The data shows the top anti-rheumatics worldwide by revenue in 2017 and a projection for 2024. Enbrel, a drug developed by Pfizer, Amgen, and Takeda, is expected to generate some four billion USD in revenue in 2024. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.
Anti-rheumatic products Some of the top anti-rheumatic products in the world include J&J, Merck & Co.
Humira (AbbVie, Eisai) | 18922 | 15233 |
Enbrel (Pfizer, Amgen, Takeda) | 8241 | 4072 |
Simponi (J&J, Merck) | 2652 | 2845 |
Otezla (Celgene) | 1279 | 2621 |
Upadacitinib (AbbVie) | 2570 |